Compare IL&FS INV. MANAGERS with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IL&FS INV. MANAGERS vs INDOCO REMEDIES - Comparison Results

IL&FS INV. MANAGERS     Change

IL&FS Investment Managers Limited (IIML) is a subsidiary of Infrastructure Leasing & Financial Services Limited (IL&FS). It was founded as Credit Capital Venture Fund (CCVF) in 1989, as an affiliate of Lazard Brothers. It was then later acquired by I... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IL&FS INV. MANAGERS INDOCO REMEDIES IL&FS INV. MANAGERS/
INDOCO REMEDIES
 
P/E (TTM) x -28.3 79.6 - View Chart
P/BV x 0.3 2.9 10.5% View Chart
Dividend Yield % 17.4 0.5 3,645.3%  

Financials

 IL&FS INV. MANAGERS   INDOCO REMEDIES
EQUITY SHARE DATA
    IL&FS INV. MANAGERS
Mar-18
INDOCO REMEDIES
Mar-18
IL&FS INV. MANAGERS/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs35317 11.1%   
Low Rs14178 7.6%   
Sales per share (Unadj.) Rs3.6113.1 3.2%  
Earnings per share (Unadj.) Rs0.24.5 4.7%  
Cash flow per share (Unadj.) Rs0.611.8 4.9%  
Dividends per share (Unadj.) Rs0.601.00 60.0%  
Dividend yield (eoy) %2.50.4 609.2%  
Book value per share (Unadj.) Rs11.473.2 15.6%  
Shares outstanding (eoy) m314.0392.15 340.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.82.2 310.9%   
Avg P/E ratio x116.855.5 210.6%  
P/CF ratio (eoy) x42.421.0 202.2%  
Price / Book Value ratio x2.13.4 63.1%  
Dividend payout %287.222.4 1,282.9%   
Avg Mkt Cap Rs m7,66222,830 33.6%   
No. of employees `000NA5.5 0.8%   
Total wages/salary Rs m4252,209 19.2%   
Avg. sales/employee Rs Th27,437.31,910.1 1,436.5%   
Avg. wages/employee Rs Th10,356.1405.0 2,557.3%   
Avg. net profit/employee Rs Th1,600.075.5 2,120.5%   
INCOME DATA
Net Sales Rs m1,12510,419 10.8%  
Other income Rs m10147 214.7%   
Total revenues Rs m1,22610,466 11.7%   
Gross profit Rs m2281,349 16.9%  
Depreciation Rs m115677 17.0%   
Interest Rs m0235 0.0%   
Profit before tax Rs m214484 44.2%   
Minority Interest Rs m-290-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11972 164.9%   
Profit after tax Rs m66412 15.9%  
Gross profit margin %20.312.9 156.7%  
Effective tax rate %55.815.0 373.2%   
Net profit margin %5.84.0 147.6%  
BALANCE SHEET DATA
Current assets Rs m2,9365,373 54.6%   
Current liabilities Rs m2414,157 5.8%   
Net working cap to sales %239.611.7 2,052.9%  
Current ratio x12.21.3 944.4%  
Inventory Days Days068 0.0%  
Debtors Days Days33473 458.9%  
Net fixed assets Rs m4816,244 7.7%   
Share capital Rs m628184 340.8%   
"Free" reserves Rs m2,9646,566 45.1%   
Net worth Rs m3,5926,750 53.2%   
Long term debt Rs m01,233 0.0%   
Total assets Rs m3,41712,363 27.6%  
Interest coverage xNM3.1-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.30.8 39.1%   
Return on assets %1.95.2 36.7%  
Return on equity %1.86.1 29.9%  
Return on capital %5.29.0 57.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m03,762 0.0%   
Fx outflow Rs m01,143 0.0%   
Net fx Rs m02,619 0.0%   
CASH FLOW
From Operations Rs m-1091,227 -8.9%  
From Investments Rs m-101-1,360 7.4%  
From Financial Activity Rs m-195-388 50.4%  
Net Cashflow Rs m-406-521 77.9%  

Share Holding

Indian Promoters % 50.5 59.2 85.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 12.5 29.4%  
FIIs % 0.4 6.0 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 45.4 22.4 202.7%  
Shareholders   31,147 12,805 243.2%  
Pledged promoter(s) holding % 100.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IL&FS INV. MANAGERS With:   REDINGTON  CENTURY PLYBOARDS  COMPACT DISC  TALWALKARS BETTER VALUE  INDIABULLS FIN. SER.  



Today's Market

Sensex Ends 429 Points Higher; Auto and IT Stocks Rally(Closing)

Indian share markets extended gains for the second consecutive day and ended on a strong note, tracking gains in Asian peers and Wall Street.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

This is How You Should Trade Intraday(Fast Profits Daily)

Jun 19, 2020

In this video, I'll show you how to trade the market intraday like a professional trader.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IL&FS INV. MANAGERS SHARE PRICE


Jul 2, 2020 03:35 PM

TRACK IL&FS INV. MANAGERS

  • Track your investment in IL&FS INV. MANAGERS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IL&FS INV. MANAGERS

IL&FS INV. MANAGERS - TVS SRICHAKRA COMPARISON

COMPARE IL&FS INV. MANAGERS WITH

MARKET STATS